Mocetinostat interferes with ZEB1, downregulating its mRNA and protein levels, and upregulates tumor-suppressing miR-203, resulting in significantly enhanced sensitivity of pancreatic cancer cells to gemcitabine therapy (Meidhof et al., 2015). This evidence concerns the gene ZEB1 and pancreatic neoplasm.